Multicenter Phase 1b/2 Trial of Nintedanib with TAS-102 in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.

Trial Profile

Multicenter Phase 1b/2 Trial of Nintedanib with TAS-102 in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Nintedanib (Primary) ; Tipiracil/trifluridine
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms N-TASK FORCE
  • Most Recent Events

    • 13 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 12 Sep 2017 Results assessing efficacy and safety, presented at the 42nd European Society for Medical Oncology Congress.
    • 11 Oct 2016 Results of phase I part presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top